Related Experiment Videos
Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma
1Department of Ophthalmology, Medical University of South Carolina, Charleston.
American Journal of Ophthalmology
|January 15, 1992
Summary
Transscleral cyclophotocoagulation using a semiconductor diode laser effectively lowered intraocular pressure in glaucoma patients. This glaucoma treatment reduced the need for medications and showed promising results for managing elevated eye pressure.
Area of Science:
- Ophthalmology
- Medical Technology
Background:
- Glaucoma is a leading cause of irreversible blindness worldwide.
- Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma progression.
- Effective IOP-lowering treatments are crucial for glaucoma management.
Purpose of the Study:
- To evaluate the efficacy of semiconductor diode laser transscleral cyclophotocoagulation (TSCPC) in reducing intraocular pressure in glaucoma patients.
- To assess changes in glaucoma medication usage post-TSCPC.
- To document complications associated with TSCPC.
Main Methods:
- Transscleral cyclophotocoagulation was performed using a semiconductor diode laser on 14 glaucoma patients.
- Specific laser parameters included 990 ms duration, 100-micron spot size, and 1200 mW power.
- Laser applications were targeted 1 mm posterior to the limbus, defocused 1 mm toward the ciliary body.
Main Results:
- Mean preoperative IOP was 34.8 mmHg, decreasing to 24.3 mmHg six months post-treatment (P < .001).
- The average number of glaucoma medications decreased from 2.2 to 1.4.
- Common complications included conjunctival burns and uveitis in all patients; one patient reported pain.
Conclusions:
- Semiconductor diode TSCPC demonstrates significant efficacy in lowering intraocular pressure in glaucoma patients.
- TSCPC may serve as a valuable therapeutic option for managing refractory glaucoma.
- Further research is warranted to optimize treatment protocols and assess long-term outcomes.